Ardea Biosciences, Inc.
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Published in Hospital Law Weekly, August 21st, 2008
Ardea Biosciences, Inc. (NASDAQ:RDEA) announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, during a late breaker session at the XVII International AIDS Conference in Mexico City.
"We are extremely pleased that the final results of the Phase 2a study presented today...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
Source: Hospital Law Weekly (2008-08-21)
More Articles from Hospital Law Weekly
- Cancer
President Bush Signs Conquer Childhood Cancer Act in White House Ceremony - Fitch Ratings
Fitch Updates Q-IFS Ratings on U.S. Property/Casualty Insurers 2 of 2 - I-Flow Corporation
I-Flow Reports 21% Increase in Total Revenues for the Second Quarter of 2008 to $35.3 Million Versus $29.1 Million for the Second Quarter of 2007 - Infectious Diseases Society of America
Higher HIV infection estimate shows need for routine screening, more funding for care - Laboratory Corporation of America Holdings
LabCorp Launches Chronic Kidney Disease Program - Life Sciences
HealthCare Insight Expands Executive Team - More from this issue of Hospital Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
